Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR001
News Source : Financial Post
News Summary
- STAR-001 is a precision oncology compound.
- The planned trial will evaluate STAR-001 as a single agent and in combination with spironolactone in pediatric patients with relapsed or refractory central nervous system (CNS) malignancies.
- The trial is planned to be conducted in collaboration with POETIC — the Pediatric Oncology Experimental Therapeutics Investigators’ Consortium — a multicenter network of 14 leading academic children’s cancer centers across the United States, Canada, and Israel.
This twopronged strategy AIguided identification of a DNA repair vulnerability, precision bioactivation of a DNAdamaging agent, and pharmacological elimination of the tumor cells repair escape rou [+8857 chars]
Never miss a story from us, subscribe to our newsletter